



Mary Rutan Hospital
205 Palmer Ave. Bellefontaine, Ohio 43311-2298
Phone: 937-592-4015

June 23, 2015

Dear Manufacturers,

I am writing on behalf of Mary Rutan Hospital (340B ID SCH360197-00) (“MRH”), to inform manufacturers that MRH recently underwent an audit by the Health Resources and Services Administration (“HRSA”) of MRH’s compliance with 340B Drug Pricing Program (the “340B Program”) requirements.

As background, MRH qualified for the 340B Program as a Sole Community Hospital and has participated in the 340B Program since September 30th, 2010.

Through the audit process, MRH was found to have non-compliance within its 340B Program and is responsible for repayment as a result of the following finding:

MRH dispensed 340B Program drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B).

MRH is in the process of identifying all affected manufacturers and will contact each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from MRH and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter, please contact Melannie Hunsicker, Director of Pharmacy at MRH, 937-599-7054, 205 Palmer Avenue, Bellefontaine, Ohio.

Very truly yours,

Steven R. Brown, Chief Financial Officer,
Vice President of Financial Services

“Progressive Quality Health Care With A Personal Touch”